Logo image of ONCO

ONCONETIX INC (ONCO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ONCO - US68237Q2030 - Common Stock

1.61 USD
+0.05 (+3.21%)
Last: 1/2/2026, 8:00:02 PM
1.66 USD
+0.05 (+3.11%)
After Hours: 1/2/2026, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, ONCO scores 1 out of 10 in our fundamental rating. ONCO was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of ONCO have multiple concerns. ONCO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year ONCO has reported negative net income.
ONCO had a negative operating cash flow in the past year.
ONCO had negative earnings in each of the past 5 years.
ONCO had a negative operating cash flow in each of the past 5 years.
ONCO Yearly Net Income VS EBIT VS OCF VS FCFONCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of ONCO (-258.38%) is worse than 90.57% of its industry peers.
ONCO has a Return On Equity of -1506.13%. This is amonst the worse of the industry: ONCO underperforms 80.00% of its industry peers.
Industry RankSector Rank
ROA -258.38%
ROE -1506.13%
ROIC N/A
ROA(3y)-101.04%
ROA(5y)-95.84%
ROE(3y)-245.67%
ROE(5y)-212.26%
ROIC(3y)N/A
ROIC(5y)N/A
ONCO Yearly ROA, ROE, ROICONCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

ONCO has a better Gross Margin (85.41%) than 88.11% of its industry peers.
The Profit Margin and Operating Margin are not available for ONCO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ONCO Yearly Profit, Operating, Gross MarginsONCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

1

2. Health

2.1 Basic Checks

ONCO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ONCO has more shares outstanding
The number of shares outstanding for ONCO has been increased compared to 5 years ago.
The debt/assets ratio for ONCO is higher compared to a year ago.
ONCO Yearly Shares OutstandingONCO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K 100K
ONCO Yearly Total Debt VS Total AssetsONCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ONCO has an Altman-Z score of -11.68. This is a bad value and indicates that ONCO is not financially healthy and even has some risk of bankruptcy.
ONCO has a worse Altman-Z score (-11.68) than 74.72% of its industry peers.
ONCO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, ONCO is in line with its industry, outperforming 41.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -11.68
ROIC/WACCN/A
WACC5.78%
ONCO Yearly LT Debt VS Equity VS FCFONCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

ONCO has a Current Ratio of 0.08. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
ONCO has a worse Current ratio (0.08) than 94.34% of its industry peers.
ONCO has a Quick Ratio of 0.08. This is a bad value and indicates that ONCO is not financially healthy enough and could expect problems in meeting its short term obligations.
ONCO has a worse Quick ratio (0.07) than 94.34% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.07
ONCO Yearly Current Assets VS Current LiabilitesONCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.69% over the past year.
Looking at the last year, ONCO shows a very negative growth in Revenue. The Revenue has decreased by -34.59% in the last year.
EPS 1Y (TTM)95.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.49%
Revenue 1Y (TTM)-34.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-25.39%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.47%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ONCO Yearly Revenue VS EstimatesONCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 500K 1M 1.5M 2M 2.5M
ONCO Yearly EPS VS EstimatesONCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -1K -2K -3K -4K

0

4. Valuation

4.1 Price/Earnings Ratio

ONCO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ONCO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ONCO Price Earnings VS Forward Price EarningsONCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ONCO Per share dataONCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ONCO!.
Industry RankSector Rank
Dividend Yield 0%

ONCONETIX INC

NASDAQ:ONCO (1/2/2026, 8:00:02 PM)

After market: 1.66 +0.05 (+3.11%)

1.61

+0.05 (+3.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13
Earnings (Next)06-01 2026-06-01/amc
Inst Owners6.26%
Inst Owner Change-44.47%
Ins Owners0.63%
Ins Owner Change15.57%
Market Cap2.51M
Revenue(TTM)1.22M
Net Income(TTM)-50.85M
Analysts43.33
Price TargetN/A
Short Float %5.31%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.05
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-350.74
EYN/A
EPS(NY)-1.01
Fwd EYN/A
FCF(TTM)-4.81
FCFYN/A
OCF(TTM)-4.81
OCFYN/A
SpS0.78
BVpS2.16
TBVpS-9.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -258.38%
ROE -1506.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.41%
FCFM N/A
ROA(3y)-101.04%
ROA(5y)-95.84%
ROE(3y)-245.67%
ROE(5y)-212.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.07
Altman-Z -11.68
F-Score5
WACC5.78%
ROIC/WACCN/A
Cap/Depr(3y)4692.79%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.49%
EPS Next Y-16.47%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-34.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-25.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.82%
OCF growth 3YN/A
OCF growth 5YN/A

ONCONETIX INC / ONCO FAQ

What is the ChartMill fundamental rating of ONCONETIX INC (ONCO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to ONCO.


What is the valuation status of ONCONETIX INC (ONCO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ONCONETIX INC (ONCO). This can be considered as Overvalued.


How profitable is ONCONETIX INC (ONCO) stock?

ONCONETIX INC (ONCO) has a profitability rating of 1 / 10.


How financially healthy is ONCONETIX INC?

The financial health rating of ONCONETIX INC (ONCO) is 1 / 10.